Patients with CLTN2 typically present with HA and some experience recurrent neuropsychiatric episodes, including behavior disturbances, nocturnal delirium, disorientation, altered consciousness, convulsive seizures, and coma.86 It is critical to distinguish CTLN2 in a patient with HA coma, as its treatment is unique. This evidence concerns the gene SLC25A13 and type 2 diabetes mellitus.